P13.26LINEAR ACCELERATOR RADIOSURGERY FOR THE TREATMENT OF NEUROFIBROMATOSIS TYPE 2 RELATED VESTIBULAR SCHWANNOMAS

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2014-09, Vol.16 (Suppl 2), p.ii71-ii71
• Main Authors: Zemskova, O., Chuvashova, O.
• Format: Article
• Language: English
• Subjects: Poster Presentations
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nou174.272

BACKGROUND: Approaches in management of neurofibromatosis type 2 related vestibular schwannomas (VS-NF2) are still controversial. All modern treatment options are less effective in controlling VS-NF2 than sporadic VS. Stereotactic radiosurgery (SRS) can be an alternative to surgery for VS-NF2. We analyzed the efficacy and side effects of SRS in treatment of patients with VS-NF2. MATERIALS AND METHODS: From 2010 till 2013 SRS was applied in twelve patients with 15 VS-NF2. Two patients were previously microsurgical operated with complete and partial removal of VS-NF2. SRS was performed by means of “Trilogy” Linear accelerator (“Varian”, USA) using stereotactic system “Brain Lab” (Germany). Median prescription dose and tumor volume were 12.5Gy (range 12.0-13.0) and 3.564cm3 (range 0.226-8.258), respectively. RESULTS: Twelve patients with 15 VS-NF2 were treated by SRS. Median follow up time was 21 months (from 6 to 35 months). In ten patients follow up was at least 12 months. Tumor growth control was achieved in fourteen (93%) tumors at the moment of the latest MRI. In seven patients after SRS no negative changes in neurological status were seen, in four of them positive changes in neurological status were seen. In three patients with VS-NF2 transitory hearing impairment appeared after SRS. No cases of resistant neuropathic trigeminal pain, considerable facial paresis and occlusive hydrocephalus after SRS were noticed. CONCLUSION: SRS is an effective non-invasive method of treatment of patients with multifocal intracranial lesions associated with NF2 and can be performed as alternative or combined treatment for selected patients.